Drug General Information
Drug ID
Former ID
Drug Name
Drug Type
Small molecular drug
Indication Idiopathic pulmonary fibrosis [ICD9: 516.3; ICD10:J84.1] Approved [556264]
Non-small cell lung cancer [ICD10:C33-C34] Phase 3 [524516], [524899], [541221]
Ovarian cancer [ICD9: 183; ICD10:C56] Phase 2 [523930], [541221]
Boehringer Ingelheim


CAS Number
CAS 656247-17-5
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Triple angiokinase Target Info Inhibitor [533123]
Vascular endothelial growth factor receptor 1 Target Info Modulator [533123]
Basic fibroblast growth factor receptor 1 Target Info Modulator [533123]
Anti-fibrotic kinase Target Info Inhibitor [533123]
Platelet-derived growth factor receptor Target Info Modulator [533123]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
PI3K-Akt signaling pathway
Focal adhesion
Transcriptional misregulation in cancer
Rheumatoid arthritishsa04010:MAPK signaling pathway
Adherens junction
Signaling pathways regulating pluripotency of stem cells
Regulation of actin cytoskeleton
Pathways in cancer
Proteoglycans in cancer
Prostate cancer
Central carbon metabolism in cancer
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Angiogenesis
FGF signaling pathway
Pathway Interaction Database Glypican 1 network
HIF-2-alpha transcription factor network
S1P3 pathway
VEGF and VEGFR signaling network
VEGFR1 specific signals
Signaling events mediated by VEGFR1 and VEGFR2glypican_1pathway:Glypican 1 network
Syndecan-4-mediated signaling events
N-cadherin signaling events
FGF signaling pathway
Reactome Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
WikiPathways Focal Adhesion
Signaling by VEGF
AngiogenesisWP51:Regulation of Actin Cytoskeleton
Endochondral Ossification
MAPK Signaling Pathway
Mesodermal Commitment Pathway
Hair Follicle Development: Induction (Part 1 of 3)
Integrated Pancreatic Cancer Pathway
Signaling Pathways in Glioblastoma
Neural Crest Differentiation
Signaling by FGFR
Ref 523930ClinicalTrials.gov (NCT01610869) Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer. U.S. National Institutes of Health.
Ref 524516ClinicalTrials.gov (NCT01979952) Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
Ref 524899ClinicalTrials.gov (NCT02231164) LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research. U.S. National Institutes of Health.
Ref 541221(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936).
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 5331232014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.